IL158445A0 - Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands - Google Patents
Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligandsInfo
- Publication number
- IL158445A0 IL158445A0 IL15844502A IL15844502A IL158445A0 IL 158445 A0 IL158445 A0 IL 158445A0 IL 15844502 A IL15844502 A IL 15844502A IL 15844502 A IL15844502 A IL 15844502A IL 158445 A0 IL158445 A0 IL 158445A0
- Authority
- IL
- Israel
- Prior art keywords
- thioxy
- heterocyclyloxy
- hydroxytryptamine
- ligands
- aminobenzazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28564301P | 2001-04-20 | 2001-04-20 | |
PCT/US2002/012415 WO2002085892A1 (en) | 2001-04-20 | 2002-04-19 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158445A0 true IL158445A0 (en) | 2004-05-12 |
Family
ID=23095111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15844502A IL158445A0 (en) | 2001-04-20 | 2002-04-19 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
Country Status (17)
Country | Link |
---|---|
US (2) | US6815456B2 (es) |
EP (1) | EP1385842A1 (es) |
JP (1) | JP4323810B2 (es) |
KR (1) | KR20030088508A (es) |
CN (1) | CN1293072C (es) |
AR (1) | AR035235A1 (es) |
BR (1) | BR0209056A (es) |
CA (1) | CA2444095A1 (es) |
EA (1) | EA200301142A1 (es) |
EC (2) | ECSP034811A (es) |
HU (1) | HUP0303958A2 (es) |
IL (1) | IL158445A0 (es) |
MX (1) | MXPA03009476A (es) |
NO (1) | NO20034648L (es) |
PL (1) | PL367297A1 (es) |
WO (1) | WO2002085892A1 (es) |
ZA (1) | ZA200309004B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK16052003A3 (en) * | 2001-06-07 | 2004-10-05 | Hoffmann La Roche | New indole derivatives with 5-HT6 receptor affinity |
CN1701477A (zh) * | 2002-02-13 | 2005-11-23 | 皇家飞利浦电子股份有限公司 | 集成半导体光学设备以及制造该设备的方法和装置 |
EP1513809A1 (en) | 2002-06-05 | 2005-03-16 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
NZ540612A (en) | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
DE102004010132A1 (de) * | 2004-02-27 | 2005-09-15 | Merck Patent Gmbh | Piperidinderivate |
GB0422263D0 (en) * | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
BRPI0517925A (pt) * | 2004-11-02 | 2008-10-21 | Pfizer | derivados de sulfonil benzimidazol |
DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
MX2007008676A (es) * | 2005-01-19 | 2007-07-25 | Hoffmann La Roche | Derivados de 5-aminoindol. |
CN101291913A (zh) * | 2005-08-15 | 2008-10-22 | 惠氏公司 | 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物 |
CN101282938A (zh) * | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
JP2009532471A (ja) * | 2006-04-05 | 2009-09-10 | ワイス | 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニル−3−ヘテロシクリルインダゾール誘導体 |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
EP2029550A2 (en) * | 2006-06-01 | 2009-03-04 | Wyeth a Corporation of the State of Delaware | 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands |
WO2009006267A2 (en) * | 2007-06-28 | 2009-01-08 | Wyeth | N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles |
WO2009034581A1 (en) * | 2007-09-11 | 2009-03-19 | Suven Life Sciences Limited | Substituted indolyl compounds and their use as 5-ht6 ligands |
WO2011143430A1 (en) | 2010-05-12 | 2011-11-17 | Abbott Laboratories | Indazole inhibitors of kinase |
EP2619198A1 (en) | 2010-09-22 | 2013-07-31 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
ME02663B (me) | 2010-10-06 | 2017-06-20 | Glaxosmithkline Llc | Derivati benzimidazola kao inhibitori pi3 kinaze |
CN104725295B (zh) | 2013-12-20 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
SG11201610407QA (en) * | 2014-07-08 | 2017-01-27 | Sunshine Lake Pharma Co Ltd | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
EP4445956A2 (en) | 2015-01-06 | 2024-10-16 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
WO2016209809A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders |
WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
CN111233736B (zh) * | 2020-03-16 | 2021-07-16 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
WO2024032530A1 (zh) * | 2022-08-11 | 2024-02-15 | 江苏恩华药业股份有限公司 | 芳杂环并环己烷基氨基烷基哌啶衍生物、制备方法及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3835291A1 (de) | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
JPH0940646A (ja) | 1995-07-27 | 1997-02-10 | Yamanouchi Pharmaceut Co Ltd | ベンゼン縮合環誘導体又はその塩 |
AU7526798A (en) * | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
AU5570900A (en) | 1999-07-01 | 2001-01-22 | Sankyo Company Limited | Indoline or tetrahydroquinoline derivatives |
CA2378047A1 (en) * | 1999-07-15 | 2001-01-25 | Methvin Isaac | Heterocyclic compounds for the treatment of migraine |
CA2432654A1 (en) * | 2000-12-22 | 2002-07-04 | Wyeth | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
-
2002
- 2002-04-19 JP JP2002583419A patent/JP4323810B2/ja not_active Expired - Fee Related
- 2002-04-19 KR KR10-2003-7013585A patent/KR20030088508A/ko not_active Application Discontinuation
- 2002-04-19 MX MXPA03009476A patent/MXPA03009476A/es active IP Right Grant
- 2002-04-19 HU HU0303958A patent/HUP0303958A2/hu unknown
- 2002-04-19 EP EP02764248A patent/EP1385842A1/en not_active Withdrawn
- 2002-04-19 WO PCT/US2002/012415 patent/WO2002085892A1/en active Application Filing
- 2002-04-19 PL PL02367297A patent/PL367297A1/xx unknown
- 2002-04-19 CN CNB028123085A patent/CN1293072C/zh not_active Expired - Fee Related
- 2002-04-19 BR BR0209056-2A patent/BR0209056A/pt not_active IP Right Cessation
- 2002-04-19 AR ARP020101442A patent/AR035235A1/es not_active Application Discontinuation
- 2002-04-19 CA CA002444095A patent/CA2444095A1/en not_active Abandoned
- 2002-04-19 IL IL15844502A patent/IL158445A0/xx unknown
- 2002-04-19 US US10/126,598 patent/US6815456B2/en not_active Expired - Fee Related
- 2002-04-19 EA EA200301142A patent/EA200301142A1/ru unknown
-
2003
- 2003-10-17 NO NO20034648A patent/NO20034648L/no not_active Application Discontinuation
- 2003-10-17 EC EC2003004811A patent/ECSP034811A/es unknown
- 2003-10-17 EC EC2003004810A patent/ECSP034810A/es unknown
- 2003-11-19 ZA ZA200309004A patent/ZA200309004B/en unknown
-
2004
- 2004-09-24 US US10/949,062 patent/US20050065186A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR035235A1 (es) | 2004-05-05 |
NO20034648D0 (no) | 2003-10-17 |
US6815456B2 (en) | 2004-11-09 |
MXPA03009476A (es) | 2004-02-12 |
BR0209056A (pt) | 2004-08-10 |
HUP0303958A2 (hu) | 2004-04-28 |
PL367297A1 (en) | 2005-02-21 |
NO20034648L (no) | 2003-11-20 |
ZA200309004B (en) | 2005-02-21 |
ECSP034810A (es) | 2003-12-01 |
KR20030088508A (ko) | 2003-11-19 |
CA2444095A1 (en) | 2002-10-31 |
EP1385842A1 (en) | 2004-02-04 |
US20030069278A1 (en) | 2003-04-10 |
EA200301142A1 (ru) | 2004-02-26 |
CN1518547A (zh) | 2004-08-04 |
ECSP034811A (es) | 2003-12-01 |
JP2004526787A (ja) | 2004-09-02 |
CN1293072C (zh) | 2007-01-03 |
US20050065186A1 (en) | 2005-03-24 |
JP4323810B2 (ja) | 2009-09-02 |
WO2002085892A1 (en) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL157059A0 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
IL158445A0 (en) | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
PL370890A1 (en) | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | |
ZA200500437B (en) | 1-heterocyclyalkyl-3-sulfonazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | |
IL155443A0 (en) | 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
ZA200500435B (en) | 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands | |
HK1066218A1 (en) | Qunazoline derivatives as antitumor agents | |
HK1065949A1 (en) | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | |
ZA200506416B (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
IL156517A0 (en) | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands | |
HK1068608A1 (en) | 3-Substituted-4-pyrimidone derivatives | |
IL156518A0 (en) | Heteocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands | |
IL158448A0 (en) | Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
HK1068607A1 (en) | Phenylalkyloxy-phenyl derivatives | |
HUP0303186A3 (en) | 4-aminobenzopyran derivatives | |
HUP0401949A3 (en) | 4-imidazolin-2-one derivatives | |
HUP0500026A3 (en) | N-heteroarylnicotinamide derivatives | |
AU2003209114A1 (en) | Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | |
EP1364954A4 (en) | Dicarba closo DODECARBORANDERIVATE | |
GB0115841D0 (en) | Ligand | |
AU2002334722A1 (en) | Chroman derivatives as 5-hydroxytryptamine-6 ligands | |
SI1427709T1 (sl) | 3-substituirani-4-pirimidonski derivati |